Stimulant Therapy for Diagnosed ADHD
A clinician prescribes a stimulant after a structured ADHD evaluation.
- ~4.4%: US adults with ADHD (diagnosed, lifetime prevalence)
- Rising: College-age Rx growth (stimulant prescriptions 18-25)
- 2 classes: First-line stimulants (methylphenidate, amphetamine)
- II: Schedule (controlled substance, DEA)
What legitimate treatment looks like
Diagnosis, dosing, and follow-up under clinical supervision.
Why stimulants are controlled
Schedule II status reflects real abuse and dependence potential.
Peer Requests and the Diversion Pathway
Diversion means sharing or selling prescribed pills to someone else.
- ~1 in 5: College misuse exposure (students asked to share/sell)
- Exam periods: Peak risk window (highest peer request rate)
- Friends/peers: Common source (not illicit dealers)
- Felony-level: Legal risk (unauthorized distribution)
Social pressure drives diversion
Requests from roommates and classmates are the main pathway.
Campus prevalence patterns
Diversion clusters around finals, papers, and high-stakes exams.
Off-Label Use for Perceived Academic Edge
Misuse means taking more than prescribed, or using without a diagnosis.
- Common myth: Non-ADHD "study aid" use (no proven cognitive benefit)
- Elevated: Overdose risk (cardiac and psychiatric effects)
- Crush/snort: Route escalation (defeats slow-release design)
- Present: Dependence potential (with repeated high-dose use)
The performance-enhancement myth
Non-prescribed use rarely improves focus in people without ADHD.
Physical and mental health risks
Higher doses raise cardiovascular and psychiatric risk sharply.
Formulation, Monitoring, Storage, and Education
Layered safeguards each blunt a different part of the risk pathway.
- Harder to misuse: Extended-release effect (resists crushing/snorting)
- PDMP: Monitoring programs (flags unusual refill patterns)
- Lockbox: Secure storage (blocks casual household access)
- Lowers sharing: Education impact (patients informed of risks)
Extended-release formulations
Slow-release matrices are harder to convert into a fast high.
Monitoring, storage, and education combined
Layering safeguards closes gaps that any single measure misses.
Reduced Risk, Preserved Legitimate Access
Combined safeguards cut diversion and misuse without denying care.
- Meaningful: Risk reduction (modeled) (with all 4 safeguards active)
- Preserved: Patient access (treatment continuity maintained)
- Layered defense: Best practice (no single safeguard suffices)
- Balance: Goal (safety without overrestriction)
Why layered safeguards work
Each safeguard blocks a different point in the risk pathway.
Sustaining safe, legitimate treatment
Ongoing monitoring keeps therapy safe without limiting real need.
Safeguards aim to reduce diversion and misuse while keeping treatment accessible for patients who need it.